Suchergebnisse - (Person:"Wagner, Kathryn R")

PubPharm (11)

1

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4) : a randomised, double-blind, placebo-controlled phase 2b trial

enthalten in: The Lancet. Neurology | 2024

von Tawil, R. | Wagner, K. | Hamel, J. | +36

2

Dual-energy X-ray absorptiometry measures of lean body mass as a biomarker for progression in boys with Duchenne muscular dystrophy

enthalten in: Scientific reports | 2022

von Sherlock, S. | Palmer, J. | Wagner, K. | +8

3

Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy : a phase 2 trial of domagrozumab

enthalten in: Journal of neurology | 2022

von Sherlock, S. | Palmer, J. | Wagner, K. | +13

4

Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy

enthalten in: Muscle & nerve | 2022

von Statland, J. | Campbell, C. | Desai, U. | +26

5

A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment

enthalten in: Journal of neuromuscular diseases | 2022

von Mitelman, O. | Abdel-Hamid, H. | Byrne, B. | +15

6

Safety and disease monitoring biomarkers in Duchenne muscular dystrophy : results from a Phase II trial

enthalten in: Biomarkers in medicine | 2021

von Wagner, K. | Guglieri, M. | Ramaiah, S. | +7

7

Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping : A randomized, double-blind, placebo-controlled, dose-titration trial

enthalten in: Muscle & nerve | 2021

von Wagner, K. | Kuntz, N. | Koenig, E. | +4

8

A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy : Results of the PolarisDMD Trial

enthalten in: Journal of neuromuscular diseases | 2021

von Finkel, R. | McDonald, C. | Lee Sweeney, H. | +24

9

Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy

enthalten in: Neuromuscular disorders : NMD | 2020

von Wagner, K. | Abdel-Hamid, H. | Mah, J. | +21

ErratumIn: Neuromuscul Disord. 2021 Feb;31(2):167-168. - PMID 33451933

10

Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy

enthalten in: Annals of neurology | 2014

von Leung, D. | Herzka, D. | Thompson, W. | +10